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ence from battling cancer such as side effects from conventional western cancer
treatment. The findings of this study suggest that cancer patients regardless of
stage may expect and satisfy with less toxic treatments with less side effects .
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OBJECTIVES: Treatment decisions for patients diagnosed with advanced non-
small cell lung cancer (NSCLC) require assessment of the risks and benefits of
treatment. We sought to understand the patient perspective when making these
choices by estimating utilities (preference weights and relative importance
weights) for different hypothetical NSCLC treatment profiles.METHODS:One hun-
dred patients with NSCLC were recruited in the UK and completed a self-adminis-
tered, web-based conjoint analysis questionnaire. The questionnaire presented
patients with pair-wise choices of NSCLC treatment profiles which systematically
varied the duration of progression-free survival (PFS), severity of disease symp-
toms, severity of the treatment-related adverse events (diarrhea, fatigue, fever/
infection, nausea/vomiting and rash) and mode of treatment administration (in-
travenous versus oral). Preference weights were estimated using a random-
parameters logit. Importance weights were calculated from the model coefficients.
RESULTS: Eighty-nine patients (73% male) completed all choice tasks appropri-
ately. The highest utility was associated with treatments that increased PFS and
improved disease-related symptom severity from severe to mild (10.0; 95% CI: 6.1,
13.9). However, patients preferred a reduction in PFS if disease-related symptoms
were severe. Utility was higher for treatments that had no fatigue (5.0; 95% CI: 2.7,
7.3), no diarrhea (2.8; 95% CI: 0.7, 4.9), no fever/infection (2.1; 95% CI: 0.2, 4.1), no
nausea/vomiting (2.1; 95% CI: 0.1, 4.1), no rash (2.0; 95% CI: 0.2, 3.9) and for oral
administration instead of infusion (1.8; 95% CI: 0.0, 3.6). Patients were found to be
indifferent to treatments associated with mild diarrhea and mild nausea/vomiting.
Avoiding moderate fatigue was half as important as increasing PFS by seven
months with improvement in symptom severity from severe to mild.
CONCLUSIONS:NSCLC patients attributed the highest utility to treatment efficacy.
Treatments that increased PFS with low severity of disease related symptoms, no
fatigue and oral administration were preferred.
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OBJECTIVES: Oral chemotherapy generates for hospitals additional resources for
therapeutic education and health care coordination currently not taken into ac-
count in reimbursement tariffs. This may influence the prescription of oral chemo-
therapy. We estimated the relative influence of the route and tariff of administra-
tion, efficacy, tolerability and adherence on physician’s preferences. METHODS: A
Discrete Choice Experiment was performed among 203 French physicians qualified
in oncology. From an online questionnaire with six fictive scenarios, first presented
in curative setting then in palliative setting, respondents had to choose between
treatment A or B which differed with respect to efficacy, tolerability, adherence and
route of administration. Three of these attributes (efficacy, tolerability, adherence)
had two modalities (good vs. moderate) and the later (route of administration) had
three modalities: intravenous (€286–379/session in private and public hospital re-
spectively), oral with the current tariff (€28/consultation), oral with a fictive tariff
(€31/consultation and €83 for a patient support program). The relative influence of
attributes was analyzed using a conditional logistic regression model. RESULTS:
Efficacy was the predominant criteria in choosing a treatment either in curative
setting ( coefficient2.114, p0.0001) or in palliative setting (1.063, p0.0001).
Oral route of administration had a positive effect in palliative setting (0.612,
p0.035 for the current tariff and 0.506, p0.0001 for the fictive tariff). Removing
the efficacy attribute of the model, tolerability (1.228, p0.0001) and adherence
(1.223, p0.0001) were influent, but only in curative setting while the oral route
with a fictive tariff remained influential only in palliative setting (0.431,
p0.0001). CONCLUSIONS: The oral route of administration was influential in pal-
liative setting, which is consistent with the priority to preserve quality of life at the
advanced stage of disease. Physicians were sensitive to the fictive tariff for a pa-
tient support program, but as expected, in curative setting the key criterion re-
mains the efficacy.
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OBJECTIVES: The national health care system encourages and supports the inte-
gration of T&CM into the conventional cancer treatment stream. The study aimed
to evaluate the perception of cancer patients towards the integration of T&CM into
their conventional therapies. METHODS: Qualitative methodology was adapted to
collect in-depth information from consented patients recruited from one of the
local hospitals with integrative medicines unit. After obtaining institutional ethical
approval, patients with different types of cancer and stages were approached.
Saturation point was reached after conducting 18 interviews as no new themes
emerged with subsequent interviews. All interviews were audiotaped, transcribed
verbatim and translated into English for thematic content analysis. RESULTS:
Mixed perceptions were shown towards the integration of traditional medicines
into the modern cancer treatment. All patients agreed with integrating traditional
therapies into their conventional health care plans only when the oncologists al-
low it. However, concerns were shown towards an implicit criticism of oncologists
regarding traditional medicines. Patients supported the use of traditional therapies
to overcome side effects due to conventional therapies provided the therapies are
proven for their safety with conventional medicines. For most of the patients,
cancer was perceived as a fatal disease and use of traditional therapies is among
the ways to put efforts for cure. Since the legitimacy of traditional medicines in the
country is among the challenges faced by the lawmakers, patients appreciated that
such efforts can prevent patients from being trapped by the quacks.
CONCLUSIONS: Patients showed signs of approval towards the integration or tra-
ditional medicines. However, patients would like their oncologists to provide and
supervise such therapies. At the same time, the challenge is to find a common
ground for an open discussion with modern health care practitioners towards
integration of traditional therapies into the modern cancer treatments.
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OBJECTIVES: Health state utilities are essential for health economic analysis. This
study assesses the utilities for different health states in breast cancer (BC ), com-
pares different HRQoL instruments and explores factors associated with poor
HRQoL. METHODS: An observational cross-sectional study among BC patients in
the Hospital District of Helsinki and Uusimaa was carried out between September
2009 and April 2011. A total of 778 BC patients (aged 31-90) assessed their HRQoL
with the generic 15D and EQ-5DVAS and the cancer specific EORTC-QLQ C30
HRQoL questionnaires. Patients were divided into five mutually exclusive groups
based on disease state: baseline before treatment (n52), 1st year of remission after
diagnosis or recurrence (n128), 2nd or following years after remission (n405),
metastatic disease (n177) and terminal care (n16). Linear stepwise regression
analysis was used to evaluate the association between the VAS-score and clinical
and demographic factors as well as the EORTC symptom and functioning scale
scores. RESULTS: The mean ( SD) utility values with 15D were for baseline pa-
tients 0.8960.083, 1st year of remission 0.9010.80, following years after remis-
sion 0.8840.103, metastatic disease 0.8250.113 and for palliative patients
0.7560.110 and with EQ-5D 0.8180.228, 0.8600.178, 0.8430.189, 0.7460.251,
0.5140.300, respectively. The difference between the instruments was consistent
in all states of the disease. In regression analysis, higher EORTC QLQ-C30 scores for
social, role and emotional functioning were associated with improved HRQoL.
However, the most important explanatory variable was higher education.
CONCLUSIONS: The utility scores were highest at 1st year of remission and dete-
riorated in the more advanced states of the disease. The 15D provided higher utility
values than the EQ-5D. The choice of the HRQoL instrument has a significant effect
on the utility values. Regression analysis showed that functioning has more impact
on HRQoL than symptoms or clinical and demographic parameters except for ed-
ucation.
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OBJECTIVES: The benefits of systemic treatment NSCLC patients are greater con-
trol of the symptoms and improvement of HRQoL. The study aimed to assess the
impact on daily living and HRQoL of the symptoms of advanced NSCLC.METHODS:
Observational study with prospective follow-up (basal and 6-8 week visit). 257
patients with stage IIIB NSCLC, with pleural/pericardial effusion or stage IV NSCLC,
about to initiate second-line treatment were included by 32 hospitals in Spain.
Demographic and clinical data relating to Lung Cancer Symptom Scale (LCSS) and
the lung-specific Functional Assessment of Cancer Therapy questionnaire
(FACT-L) were collected. Specific questions evaluating impact of symptoms on
patient daily life were included. RESULTS: By gender, 79.4% of patients were men,
the mean (SD) age was 63.7 (10.0) years. ECOG 1 was presented by 56.4% and 38.9%
A459V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) A 2 3 3 - A 5 1 0
